<?xml version="1.0" encoding="UTF-8"?>
<Progress_Report_Checklist
><Grant_Information
><RFA_Number
>06-01</RFA_Number
><Grant_Number
>RS1-00203-1</Grant_Number
><Reporting_Period_Start
>8/1/2008</Reporting_Period_Start
><Reporting_Period_End
>7/31/2009</Reporting_Period_End
><Institution_Name
>University of California, Los Angeles</Institution_Name
><Primary_Investigator
><Prefix
/><First_Name
>Zoran</First_Name
><Middle_Name
/><Last_Name
>Galic</Last_Name
><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
/><Telephone_Number
/><Extension
/><Fax_Number
/></Primary_Investigator
></Grant_Information
><Reviewer_Information
><Grants_Manager
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>ewhite-negrete</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Grants_Manager
><Science_Officer
><Prefix
/><First_Name
/><Middle_Name
/><Last_Name
/><Suffix
/><Degree
/><Institution
/><Title
/><Department
/><Email
>stalib</Email
><Telephone_Number
/><Extension
/><Fax_Number
/></Science_Officer
></Reviewer_Information
><Reviews
><Budget_Review
><IsRequired
/><Grant_Manager_Notes
>Budgets for Year 2 &amp; NCE submitted and approved.</Grant_Manager_Notes
><Science_Officer_Notes
>Made good progress in the project. Need to tie loose ends</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Budget_Review
><California_Supplier_Review
><IsRequired
/><Grant_Manager_Notes
>80% CA supplier reported</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
/><IsComplete
/></California_Supplier_Review
><Key_Personnel_Review
><IsRequired
/><Grant_Manager_Notes
/><Science_Officer_Notes
>PI = 40%; Research scientist = 50% and SRA = 100%</Science_Officer_Notes
><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Key_Personnel_Review
><IACUC_Assurances_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>Approval lists PI, CIRM grant title and award number; approval from 5/11/2009-5/10/2010.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></IACUC_Assurances_Review
><IRB_Assurances_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></IRB_Assurances_Review
><SCRO_Assurances_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>PI name, CIRM grant title and award number listed; approval period from 8/4/2009-8/3/2010.</Grant_Manager_Notes
><Science_Officer_Notes
/><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></SCRO_Assurances_Review
><Publication_Reporting_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
>PI listed &amp; submitted a published article; GM emailed on 5/19 for publication &amp; disclosure form.</Grant_Manager_Notes
><Science_Officer_Notes
>Need publication disclosure completed</Science_Officer_Notes
><Grant_Manager_Approval
>1</Grant_Manager_Approval
><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/></Publication_Reporting_Review
><Invention_Licensing_Review
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Invention_Licensing_Review
><PI_Effort_Review
><IsRequired
>1</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
/><Science_Officer_Approval
>1</Science_Officer_Approval
><IsComplete
/><Total_Current_Effort
>95</Total_Current_Effort
><CIRM_Award_Effort
>40</CIRM_Award_Effort
></PI_Effort_Review
></Reviews
><Award_Conditions
><Conditions_Exist
>0</Conditions_Exist
><Conditions_Met
><Conditions_Met
/><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>0</Science_Officer_Approval
></Conditions_Met
><New_Conditions
><New_Conditions
>0</New_Conditions
><Grants_Manager_Notes
/><Grants_Manager_Approval
>0</Grants_Manager_Approval
><Science_Officer_Notes
/><Science_Officer_Approval
>0</Science_Officer_Approval
></New_Conditions
></Award_Conditions
><Prior_Approval
><IsRequired
>0</IsRequired
><Grant_Manager_Notes
/><Science_Officer_Notes
/><Grant_Manager_Approval
>0</Grant_Manager_Approval
><Science_Officer_Approval
>0</Science_Officer_Approval
><IsComplete
/></Prior_Approval
><Evaluation
><Overall_Rating
>Better than expected</Overall_Rating
><Translational_Status
>No substantial change, incremental, or N/A</Translational_Status
><Executive_Summary
>June 28, 2010&#xD; &#xD;RS1-00203&#xD;&#xD;Genetic enhancement of the immune response to Melanoma via hESC-derived T cells &#xD;&#xD;• Substantial progress&#xD;&#xD;Aim 1:  Generate hESC-derived transgenic T cells expressing high affinity T cell receptor for MART1 melanoma antigen&#xD;&#xD;• Manuscript publication in Stem Cells  “ Generation of T lineage cells from hESC in a feeder free system “  Stem Cells 2009, 27:100.&#xD;• Generated MART transgenic hESC-derived T cells in SCID-hu mice&#xD;• Generation of MART1-specific hESC-derived T cells in BLT model of hematopoiesis&#xD;&#xD;Aim 2: Functional activity of the hESC-derived T cells&#xD;&#xD;• Phenotypic and functional characterization was performed. &#xD;o hESC-derived TCR T cells when stimulated with appropriate APC (MART-1 pulsed fibroblasts) expressed T cell maturation markers as well as g-INF. Antigen specificity shown by tetramer staining.&#xD;• MART-specific T cells generated in SCID-hu mice were tested for functionality by in vitro cytotoxicity assay by FACS assay&#xD;• In vivo  - NSG mice reconstituted with hESC –derived HSC –transgenic for MART-TCR – generation of MART-1 positive T cells  (CD8, CD4). &#xD;• Further functional characterization for anti-MART-1 tumor activity in vivo in BLT mice is in progress. &#xD;&#xD;Summary: Overall, apart from the demonstration of  anti-tumor activity in vivo. Team has made substantial progress in generating hESC-derived HSC , engraftment in SCID and BLT mice and in vitro functionality.&#xD;</Executive_Summary
></Evaluation
><Strategic_Outcome
><Five_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_1
><Five_Year_Goal_2
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>Generated hESC line with MART antigen specific TCR gene</Outcomes
><Impact_Factor
>2</Impact_Factor
></Five_Year_Goal_2
><Five_Year_Goal_3
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_3
><Five_Year_Goal_4
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>Generated T lineage cells from hESC in feeder free system</Outcomes
><Impact_Factor
>2</Impact_Factor
></Five_Year_Goal_4
><Five_Year_Goal_5
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_5
><Five_Year_Goal_6
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_6
><Five_Year_Goal_8
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Five_Year_Goal_8
><Ten_Year_Goal_1
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_1
><Ten_Year_Goal_2
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_2
><Ten_Year_Goal_5
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>POC of antigen specific immunotherapy with hESC-derived HSC targeting melanoma tumor in scid and BLT model </Outcomes
><Impact_Factor
>2</Impact_Factor
></Ten_Year_Goal_5
><Ten_Year_Goal_7
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_7
><Ten_Year_Goal_8
><IsApplicable
>1</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
>hESC derived HSC and further differentiation of HSC to immune system cells (T and NK cells)</Outcomes
><Impact_Factor
>2</Impact_Factor
></Ten_Year_Goal_8
><Ten_Year_Goal_9a
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_9a
><Ten_Year_Goal_9b
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_9b
><Ten_Year_Goal_10
><IsApplicable
>0</IsApplicable
><IsComplete
>1</IsComplete
><Outcomes
/><Impact_Factor
/></Ten_Year_Goal_10
></Strategic_Outcome
><IsComplete
/></Progress_Report_Checklist
>